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Abstract 
Background: The major therapeutic benefit of hydroxyurea, the only FDA-approved pharmacologic treatment for 
sickle cell disease (SCD), is directly related to fetal hemoglobin (HbF) production that leads to significant reduction of 
morbidity and mortality. However, potential adverse effects such as infertility, susceptibility to infections, or terato-
genic effect have been subject of concerns. Therefore, understanding HU molecular mechanisms of action, could lead 
to alternative therapeutic agents to increase HbF with less toxicity. This paper investigated whether HU-induced HbF 
could operate through post-transcriptional miRNAs regulation of BCL11A, KLF-1 and MYB, potent negative regula-
tors of HbF. Both ex vivo differentiated primary erythroid cells from seven unrelated individuals, and K562 cells were 
treated with hydroxyurea (100 μM) and changes in BCL11A, KLF-1, GATA-1, MYB, β- and γ-globin gene expression were 
investigated. To explore potential mechanisms of post-transcriptional regulation, changes in expression of seven tar-
geted miRNAs, previously associated with basal γ-globin expression were examined using miScript primer assays. In 
addition, K562 cells were transfected with miScript miRNA inhibitors/anti-miRNAs followed by Western Blot analysis to 
assess the effect on HbF protein levels. Direct interaction between miRNAs and the MYB 3′-untranslated region (UTR) 
was also investigated by a dual-luciferase reporter assays.
Results: Down-regulation of BCL11A and MYB was associated with a sevenfold increase in γ-globin expression in 
both primary and K562 cells (p < 0.003). Similarly, KLF-1 was down-regulated in both cell models, corresponding to 
the repressed expression of BCL11A and β-globin gene (p < 0.04). HU induced differential expression of all miRNAs in 
both cell models, particularly miR-15a, miR-16, miR-26b and miR-151-3p. An HU-induced miRNAs-mediated mecha-
nism of HbF regulation was illustrated with the inhibition of miR-26b and -151-3p resulting in reduced HbF protein 
levels. There was direct interaction between miR-26b with the MYB 3′-untranslated region (UTR).
Conclusions: These experiments have shown the association between critical regulators of γ-globin expression 
(MYB, BCL11A and KLF-1) and specific miRNAs; in response to HU, and demonstrated a mechanism of HbF production 
through HU-induced miRNAs inhibition of MYB. The role of miRNAs-mediated post-transcriptional regulation of HbF 
provides potential targets for new treatments of SCD that may minimize alterations to the cellular transcriptome.
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Background
Sickle cell disease (SCD) occupies a prominent place in 
human genetics, as the paradigmatic example of a mono-
genic disorder, that was described over 100  years ago, 
and in 1949, it became the first human disease to be deci-
phered at the molecular level [1]. SCD is a monogenic, 
hematological and multi-organ disorder associated acute 
and chronic illness, and progressive organ damage [2]. 
The disease is due to a single point mutation (Glu6Val) 
that causes polymerization of the mutant hemoglobin 
(Hb) S, resulting in sickling of erythrocytes. Inflamma-
tion, hemolysis, microvascular obstruction and organ 
damage characterize the clinical expression of SCD, 
which is highly variable in individual patients [3]. Sub-
Saharan Africa (SSA) has the highest disease burden 
with approximately 305,800 affected new-borns per year, 
accounting for 0.74 % of all births in the region (Modell 
et al. 2008) and 80 % of annual global affected child births 
[4]. Despite this high incidence, the life-saving public 
health programs have not been implemented in most 
SSA countries often associated with limited medical 
resources and infrastructures. As a consequence, neona-
tal and childhood mortality due to SCD remains high and 
estimates suggest that without intervention, up to 90 % of 
affected children in SSA die by age five from SCD [4, 5]. 
Nevertheless, SCD patients manifest with wide varying 
degrees of severity. In combination with environmental 
factors, several genomic loci, influence the clinical course 
of SCD. Indeed, despite the fact that there are several 
key phenotypes of SCD (anemia, stroke, infections), fetal 
hemoglobin (HbF) has emerged as a central disease mod-
ifier [3], that is amenable to therapeutic manipulation [6]. 
Genetic variants at three principal loci, BCL11A, HBS1L-
MYB and HBB cluster account for 10–20 % of HbF vari-
ation [7–9]; among SCD patients in USA and Brazil [10], 
Tanzania [5] and Cameroon [11]. Currently, hydroxyurea 
(HU) is the only FDA-approved pharmacologic treatment 
for the induction of HbF in patients with SCD. The major 
HU benefit is directly related to its HbF-producing effect 
[12, 13] that leads to significant reduction of pain, acute 
chest episodes, mortality and the need for blood transfu-
sions [14–17]. HU has also been associated with clinical 
drift, where physicians use the drug for related compli-
cations of SCD such as stroke prevention, priapism and 
pulmonary hypertension [18]. However potential short 
and long term adverse effects such as infertility [18–20], 
susceptibility to infections [21–24], potential terato-
genic effect [25, 26], have also been associated with HU. 
The fear of such side-effects has been a subject of con-
cern to some professionals [27, 28], parents as well as 
patients [29–33] and a potential barrier to compliance 
in some settings [34, 35]. As a consequence, HU is still 
underutilized [29, 30]. It is then urgent to fully under-
stand HU molecular mechanisms of action, in order 
to explore alternative and potential less toxic and more 
acceptable agents that could equally increase the level of 
HbF.
Several other HU-mediated mechanisms of disease 
amelioration have been reported including production of 
nitric oxide, regulation of soluble guanylyl cyclase, cyclic 
adenosine and guanosine monophosphate [36, 37] as 
well as erythropoietic stress response [38]. Furthermore, 
various signalling pathways have been implicated in HU-
mediated fetal hemoglobin (HbF) induction such as the 
Giα/JNK/Jun [39]; p38/MAPK/CREB1 [40]; cAMP-medi-
ated response [41, 42]; erythropoietin (EPO)-induced 
activation of the ERK-1/ERK-2 MAPK [43]; histone dea-
cetylase (HDAC) and DNA methyl-transferase (DNMT) 
inhibitor-mediated epigenetic modification of γ-globin 
expression. Despite this, a complete understanding of 
HU-mediated HbF production remains incomplete.
Post-transcriptional regulation of γ-globin expression 
through micro RNAs (miRNAs) has been shown to play 
an important role in HU-mediated HbF induction as HU 
causes differential expression of a suite of miRNAs associ-
ated with basal and γ-globin expression at maximum toler-
ated dose (MTD) in SCD patients [44, 45]. Likewise, DNA 
methylation has been significantly associated with baseline 
HbF [38, 46, 47] but provided no substantial explanation 
for HbF induction in response to HU. Small non-coding 
RNAs, particularly miRNAs, however, have emerged as 
powerful regulators and modifiers of gene expression 
through inhibition of mRNA translation [48], which has 
implications for hematopoiesis and erythropoiesis [49, 50], 
particularly in the distinct miRNA expression patterns in 
SCD patients [51] and the severity of anaemia [52]. More-
over, a few reports have specifically implicated the miR-
NAs in the regulation of HbF [44, 53, 54].
This study has further investigated whether the induc-
tion of HbF by HU treatment could operate through 
post-transcriptional regulation of BCL11A, KLF-1 and 
MYB, by analysing changes in expression of select miR-
NAs in erythroid cells derived from umbilical cord blood 
CD34+ hematopoietic stem cells and the K562 cell line.
Results
CD34+ hematopoietic cells
The average volume of umbilical cord blood collected was 
108  ml (±25  ml) with a 1.3  % (±0.5  %) yield of CD34+ 
cells at an average 87 % (±6 %) percentage purity of the 
cell population after Dynabead magnetic separation tech-
nology (Fig. 1a). The CFU-GEMMs also produced several 
burst-forming unit-erythroid cells (BFU-E) and erythroid 
clusters typically formed during expansion (Fig. 1b).
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Ex‑vivo differentiation of CD34+ cells
CD34+ cells were cultured using an ex vivo single-phase 
expansion and differentiation protocol and all pri-
mary CD34+ primary lines were successfully expanded 
(mean fold expansion 4.2; ±  2.7) and differentiated into 
erythroid progenitors with average expression of 84  % 
(±3 %) and 83 % (±8 %) for CD235a and CD71, respec-
tively (Fig.  1a). The first half of the expansion and dif-
ferentiation was characterized by cluster-like colonies 
of erythroid cells and sparse loose-lying cells (Fig. 1b, c). 
During early differentiation (days 1–3) large blasts were 
observed in culture followed by proerythroblast mor-
phology around day 5. The morphology typical of baso-
philic erythroblasts was observed on days 7–8 (Fig.  1b) 
and on day 15, the majority of the cells had ortho/poly-
chromatophilic morphology, which was confirmed by 
the expression of cell-surface markers CD71 and CD235a 
(Additional file  1: Figure S1), at which point differen-
tiation was halted and cells treated with HU for various 
analyses.
WST‑1 cell proliferation assay
To determine the optimal concentration and exposure 
time to HU, K562 cells (8 × 104 cells) were treated with 
varying doses of HU and for 2, 4, 6, 12 and 24 h. Six hour 
(6) exposure time and 100  µM were determined to be 
optimal as there was minimal initial cytotoxic effect and 
sufficient cellular metabolic activity to alter gene expres-
sion in response to HU (Additional file 2: Figure S2).
Hydroxyurea induces γ‑globin expression in both erythroid 
and K562 cells
Erythroid progenitors from seven unrelated individu-
als and the K562 cell line were successfully analysed for 
Fig. 1 Flow cytometry showing differentiation of CD34+ cells to erythroid progenitors (a) and the cluster-like basophilic erythroblast morphology 
of erythroid cells on day 7 of differentiation (b) and the colony-forming hematopoietic cell units (CFU-E) (c). CD34+ hematopoietic stem cells were 
purified from umbilical cord blood mononuclear cells using Dynabead magnetic separation to a purity of 87.6 %. After the 15 day single-phase 
ex vivo expansion and differentiation, the cell population was 92.7 and 78.2 % CD235a+ and CD71+, respectively with minimal CD34 positivity. This 
confirmed our differentiation and provided erythroid cells for down-stream experiments (a). During the expansion and differentiation of HSCs to 
erythroid cells, the cells formed cluster-like colonies before separating into single cells in suspension, which was typical of terminal differentiation 
(b). The hematopoietic colony formation assay was performed to confirm the stem-like behaviour of the Dyna-bead selected CD34+ HSCs prior to 
expansion and differentiation. The colony-forming unit- granulocyte, erythroid, monocyte, megakaryocyte (CFU-GEMM) semi-solid cultures were 
grown for 14 days and stained for colony counting (c)
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differential gene expression in response to HU treatment, 
with three technical and independent qPCR experimen-
tal repeats for K562 cells and one experimental repeat for 
ex vivo derived erythroid cells due to the limited number 
of cells. Subsequently, four of the ex  vivo derived lines 
were analysed for corresponding miRNA expression. 
HU treatment of K562 cells showed a sigmoidal pattern 
of expression in BCL11A transcription with an apparent 
down-regulation at 6  h, an expression pattern inverse 
to the γ-globin that showed a sevenfold upregulation 
at the same HU exposure time (Fig. 2). KLF-1, a critical 
activator of BCL11A [55], and MYB, a potent activator 
of KLF-1 [56, 57] and negative regulator of γ-globin [58] 
had similar expression patterns and were significantly 
down-regulated at 12 h (p < 0.03). β-Globin and GATA-1 
expression remained largely unaffected by HU treatment 
with the exception of a slight down-regulation also after 
12 h treatment.
The gene expression pattern in the primary erythroid 
lines was largely similar to that in K562 cells with an 
inverse relationship between γ-globin expression and its 
critical regulators; BCL11A, KLF-1 and MYB. Some pri-
mary lines had a sevenfold (p  <  0.003) up-regulation of 
γ-globin expression  6  h after HU treatment associated 
with the down-regulation of MYB (p < 0.04) and BCL11A 
expression (Fig.  3). Gene expression analysis was done 
after successful ex vivo differentiation of primary eryth-
roid cells and HU treatment for 24 h.
Hydroxyurea up‑regulates miRNAs associated 
with inhibition of BCL11A and MYB
In the primary lines analysed for miRNAs expression 6 h 
post treatment, there was inter-individual variation in 
expression however, miR-26b was significantly down-reg-
ulated in all but one primary line (Fig. 4). HU treatment 
also caused sigmoidal time-dependent changes in miR-
NAs expression in K562 cells (Additional file  3: Figure 
S3), with significant up-regulation of miR-15a and miR-
16-1 at 6 h (p value 0.027 and 0.002, respectively), which 
are known inhibitors of MYB [54]. MiR-151-3p and miR-
451 were also significantly up-regulated at 6 h post treat-
ment (0.041 and 0.042, respectively) and although not 
statistically significant, miR-494 had a twofold increase. 
All miRNAs were down-regulated 12  h after treatment 
and returned to baseline after 24 h.
MicroRNA inhibition
The inhibition of miR-26b and miR-151-3p resulted in a 
significant decrease in γ-globin expression (Fig. 5), which 
could be partially rescued when cells were treated with 
HU. This suggests that most miRNAs target negative reg-
ulators of HbF as their inhibition causes up-regulation of 
γ-globin expression. At a higher concentration (25 nM), 
all miRNAs down-regulated HbF (Additional file 4: Fig-
ure S4). Cells were co-transfected with select pairing of 
miRNAs in order to investigate the combinatorial effect 
of anti-miRNAs. The effect of miR-26b/miR-151-3p and 
miR-151-3p/miR-494 were comparable in the decrease of 
HbF. Although the inhibition of miR-494 had no appar-
ent effect on HbF, co-transfection with miR-26b resulted 
in near-complete transient knock-down of HbF.
MiR‑26b directly targets MYB 3′‑UTR
Given the clear association between (i) HU and MYB 
expression; (ii) HU and our candidate miRNAs and 
(iii) the miRNAs and MYB expression patterns, dual-
luciferase reporter assays were conducted using the 
pGL3-MYB-3′UTR to investigate the potential direct 
interactions between our candidate miRNAs and the 
MYB-3′-UTR (1191 base pairs). The amount of lucif-
erase activity from the vector is directly proportional 
to the miRNAs occupancy of the UTR, which is known 
to induce mRNA transcript degradation via the RNA-
induced silencing complex (RISC) [59]. There was a 
2.2-fold increase in luciferase activity when cells were co-
transfected with anti-miR-26b (Fig.  6a) and similarly, a 
time-dependent change in luciferase activity in response 
to HU treatment, with the highest luciferase activity 
observed after 12  h of HU treatment. Similarly, how-
ever less apparent, luciferase activity was observed with 
the transfection of anti-miR-151-3p, anti-miR-451 and 
anti-miR-494 (Additional file  5: Figure S5). To confirm 
that miR-26b directly interacts with the MYB 3′-UTR 
and initiates RISC-mediated mRNA degradation, there 
was gradual recovery of the luciferase activity with the 
decrease in concentration of the transfected anti-miR-
26b (Fig. 6b). Therefore, at low anti-miR-26b concentra-
tion (2.5 nM), endogenous miR-26b is permitted to bind 
the MYB 3′-UTR, which would result in MYB mRNA 
degradation and therefore up-regulation of γ-globin 
expression.
Discussion
Although HU has demonstrated significant clinical 
improvements in SCD patients, a complete understand-
ing of the myriad of molecular mechanisms by which 
HU induces the disease-ameliorating HbF remain elusive 
[60]. This paper demonstrates the post-transcriptional 
effect of HU on critical regulators of γ-globin expres-
sion and associated miRNAs using two models; erythroid 
cells derived from umbilical cord blood CD34+ HSCs and 
K562 cells. Cord blood-derived CD34+ cells are an abun-
dant, non-invasive and largely unutilised source of HSCs 
and a good model to investigate erythropoiesis [61, 62] 
and elucidate the molecular mechanisms of HbF produc-
tion in response to therapeutic agents [63]. The volume 
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of cord blood collected in this study was consistent with 
expected norms [64] although the average CD34+ cell 
yield was slightly lower, possibly due to our stringent cell 
separation method. Erythroid cells were successfully dif-
ferentiated using an ex vivo single-phase expansion and 
differentiation protocol [65] with minor alterations to 
achieve optimal ex vivo expansion [66]. Given that HU is 
thought to induce γ-globin via perturbation of erythroid 
cell maturation [36, 67], in this study HSCs were differen-
tiated to orthochromatophilic erythroblasts for 15  days. 
It has been previously demonstrated that cells treated 
with HU around day 6 and harvested at day 10 of differ-
entiation consist mostly of basophilic and polychromat-
ophilic normoblasts, comparable to untreated cultures 
at a similar stage [68]. In another study, investigating 
the effect of HU on BCL11A, KLF-1 and TAL-1 in bone 
marrow-derived basophilic erythroblasts, post terminal 
differentiation, there was no significant difference in the 
expression of the markers of late erythroid differentiation, 
CD235a and CD71, between HU treated and untreated 
cells [54]. Likewise in this study, the comparable levels of 
CD235a and CD71 between pairwise samples (HU+ and 











































































Fig. 2 Time-dependent gene expression changes in K562 cells treated with hydroxyurea Hydroxyurea induced inverse time-dependent sigmoidal 
expression of BCL11A and HBG-1 (HbF) with the highest fold increase in HbF corresponding to the lowest BCL11A expression between 6 and 12 h 
after HU treatment. KLF-1, an activator of BCL11A, also followed a similar trend, lowest after 12 h of HU treatment. GATA-1 was also down-regulated 
at the same time point as well as the negative regulator, MYB. * Significant difference, p < 0.05
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HU−) confirms that at the point of expression analyses, 
the paired samples were at a similar maturation stage 
(Additional file 1: Figure S1), and thus the erythroid cell 
maturation cannot account for the observed changes in 
expression. It is thus more likely that the observed induc-
tion of γ-globin is a result of the repression of BCL11A, 
KLF-1 and MYB. Therefore, with further development of 
expansion and differentiation protocols, the use of cord 
blood stem cells can be extended to routine laboratory 
disease modelling and testing of therapeutic agents above 
and beyond the curative transplantation value of this bio-
logical material.
The WST-1 assay, a non-radioactive spectrophoto-
metric quantification of cellular metabolic activity and 
proliferation was used to determine the optimal HU 
concentration and cellular incubation periods within 
a 24 h period given that HU is commonly prescribed to 
SCD patients as a daily oral drug [69]. The most apparent 
effects of HU on γ-globin, its critical regulators (BCL11A, 
MYB, KLF-1) and erythroid transcription factor, GATA-
1, was between 6 and 12  h after 100  µM treatment, at 
which time cellular metabolic activity was sufficient to 
assess changes in gene expression.
Using paired analysis, we demonstrated a sevenfold 
(p < 0.003) up-regulation of γ-globin expression and cor-
responding down-regulation of BCL11A in both eryth-
roid and K562 cells (Figs. 2, 3). BCL11A has been shown 
to be a critical negative regulator of γ-globin and funda-
mental to the ‘fetal switch’ from γ- to β-globin expression 
[58]. Furthermore, it has been successfully shown to be 
responsive to therapeutic manipulation for potential SCD 
treatment [65]. The time-dependent patterns of BCL11A 
and γ-globin gene expression are inversely related, with 







































































































Fig. 3 Hydroxyurea-induced gene expression changes in ex vivo derived erythroid cells. The gene expression profiles of primary erythroid lines 
after HU treatment for 6 h. Although the expected inter-individual variation in expression was observed, there were several common trends such 
the low BCL11A, KLF-1 and MYB; and significant upregulation of HbF expression. HBB (β-globin) expression was always associated with BCL11A, 
which is expected given the role of this transcription factor in the “fetal switch”. * Significant difference, p < 0.05
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K562 cells. Similarly, KLF-1 was down-regulated in both 
cell models, corresponding to the repressed expression 
of BCL11A and β-globin gene (p  <  0.04). This result is 
consistent with the function of KLF-1 as an activator of 
BCL11A and its association with haplo-insufficiency-
induced hereditary persistence of fetal hemoglobin [55]. 
GATA-1 expression was similar to KLF-1, which is con-
sistent with evidence that this principal erythroid tran-
scription factor co-occupies the 5′ locus control regions 
and 3′ DNase I-hypersensitivity site of the β-globin gene 
cluster and associates with BCL11A in the Mi-2/nucleo-
some remodelling and deacetylases (NuRD) complex and 
therefore possibly critical in the repression of HbF pro-
duction [58, 65, 70]. Down-regulation of MYB in both 
erythroid and K562 cells corresponded with induction of 
γ-globin expression and was inversely related to miR-26b 
as well as miR-15a and miR-16-1, which have been impli-
cated in the elevation of HbF production via directly tar-
geting the MYB transcription factor [45]. Although HU 
induced down-regulation of BCL11A; KLF-1 and MYB, 
the effect on γ-globin expression was variable, which sug-
gests that HU may interact with many genes upstream 
of γ-globin induction and also induce other post-tran-
scriptional changes of gene expression through miRNAs. 
Recently similar effects of HU on BCL11A and KLF-1 
were demonstrated in late differentiation erythroblasts 
derived from bone marrow progenitors, also implicating 
TAL-1 in the regulation of BCL11A; KLF-1 via promoter-
binding and MYB repression [54]. Furthermore, K562 
cells were previously used to demonstrate the crucial role 
of TAL-1 as the DNA-binding component of the LDB-1 







































































































































































Fig. 4 Hydroxyurea induces differential expression of miRNAs associated with BCL11A and MYB repression in erythroid cells. Treatment of primary 
cells with HU causes differential regulation of miRNAs as early as 6 h post treatment. There is inter-individual variation in expression however, miR-
26b was significantly down-regulated in all but one primary lines. And conversely, miR-451 is down-regulated in all but 1 of the erythroid lines. HU 
induces variation in the expression of miRNAs associated with key regulators of HbF. * Significant difference, p < 0.05
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gene cluster to allow interaction between the 5′-LCR and 
the β-globin gene [71]. Taken in sum with the results of 
the present study, HU induces γ-globin through numer-
ous networks comprising BCL11A, KLF-1, TAL-1 and 
MYB. The data of this study also demonstrated an asso-
ciation between miR-26b and γ-globin expression, which 
has previously been shown both at basal and MTD in 
HU-treated SCD patients [44]. There was a 4.5-fold up-
regulation of miR-16-1 and miR-151-3p in K562 cells 
(Additional file  3: Figure S3), which was related to the 
most apparent induction of HbF at 6  h after HU treat-
ment. A direct target of DNMT-1, miR-148a [72], was 
also up-regulated 6  h after HU treatment, which corre-
lated to γ-globin induction. These findings suggest that 
the observed HbF production may also be through other 
post-transcriptional regulatory modalities such as meth-
ylation inhibition in the β-globin gene cluster.
The inhibition of the miRNAs, particularly miR-26b, 
unequivocally demonstrates a causative effect by HU on 
the induction of HbF through miRNA-mediated mech-
anisms. This is further supported by the near-complete 
transient knock-down of HbF when miR-26b and miR-
494 are co-inhibited. The inhibition of miR-26b, miR-
151-3p and miR-451 results in apparent decreases in 
HbF in comparison to all controls (inhibitor negative 
control; untransfected and HU treated cells). This effect 
is likely because miR-26b inhibits MYB translation, 
causing reduced KLF-1 activation and thus lowering 
BCL11A expression, thereby increasing HbF produc-
tion (Figs.  5, 6, 7). Therefore these data highlight the 
critical role played by potent negative regulators of HbF 
such as MYB, KLF-1 and BCL11A and demonstrate 
that miRNAs provide a viable therapeutically respon-
sive tier of HbF production for SCD treatment (Fig. 7), 
importantly while sparring the undruggable nature 
these transcription factors in non-erythroid cells 
[73]. Overall, the K562 cell experimental repeats were 
similar and although there was expected inter-indi-
vidual variation in the degree and timing of up- and/
or down-regulation of γ-globin and its key regulators 
in the erythroid model, the trends remained true and 
largely comparable. Despite the fact that several studies 
have and continue to utilise K562 as a model to inves-
tigate various components of γ-globin expression [39, 
53, 74–77], it could be argued that K562 cells are not 
an ideal model for studying globin switching because 
of their bias expression of γ-globin. We however, saw 
this as an advantage in a number of ways: (1) the aim 
of this study was not to demonstrate the switching in 
expression of the globin genes (β to γ) but rather to 
use a stable cell line model in conjunction with cord 
blood-derived erythroid cells to demonstrate increases 
in γ-globin and decreases its regulators (BCL11A, KLF-
1 and MYB) in response to HU, and for this purpose, 
K562 cells would suffice as a model; (2) in choosing the 
whether to use miRNA mimics or anti-miRNAs (miR-
inhibitors), the high expression of γ-globin in K562 was 
considered; if our hypothesis of HU-induced miRNA-
mediated repression of MYB was correct, the use of 
mimics would not only introduce unnaturally high lev-
els of miRNAs into this model (which we felt may in 
fact result in some artefactual results merely because of 
this unnatural state of aberrant concentration of miR-
NAs in the cells) but it would also be compounded by 
any co-treatments with HU in causing γ-globin expres-
sion. This rationale led to the choice of anti-miRNAs, 
which would go toward decreasing the already high lev-
els of γ-globin in K562 (via MYB) and also provide an 
obvious opportunity of the rescue of miR-26b inhibi-
tion with HU co-treatment.
a
b
Fig. 5 Inhibition of candidate miRNAs down-regulates HbF in K562 
cells. The effect of anti-miRNAs (5 mM) on HbF protein levels in K562 
cells (western blot analysis—a; western blot densitometric illustra-
tion—b). Inhibition of miR-26b and miR-151-3p results in decreased 
HbF levels in comparison to the control anti-miRNA. HbF expression 
is partially recovered with HU treatment. All anti-miRNAs co-trans-
fections result in reduced HbF levels, particularly co-transfection of 
anti-miR-26b and anti-miR-494 resulting in near-complete transient 
knock-down of HbF
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Future work: implications for novel therapeutics in SCD
Future work regarding the post-transcriptional mecha-
nisms regulating the expression of various trans-acting 
factors, such as BCL11A, KLF-1 and MYB, could include 
experimental variations of the level of candidate miRNAs 
and examination of the effect on HbF levels and addi-
tional 3′-UTR luciferase assays on such regulators. The 
limitation on the number of primary erythroid cells could 
be overcome by the use of improved primary cell trans-
fection protocols or alternative sources of HSCs such as 
commercially available HSCs or bone marrow aspirates. 
Future work will look to replicate these results in primary 
erythroid cells and investigate other candidate miRNAs 
for interactions with key regulators of γ-globin expres-
sion. Another limitation of the present work the “promis-
cuous” nature of HU, as it could influence many aspects 
of cellular functions and almost certainly alter the global 
cellular transcriptome. Therefore, future studies should 
continue to evaluate the in  vivo impact of efficacious 
concentrations of HU on the erythroblast transcriptome 
and/or proteome, as well as the erythroid-specific micro-
nome of SCD patients (before treatment and at MTD) 
as global analysis of these epigenetic mechanisms could 
highlight multiple components of this complex system 
and possibly yield alternative (possibly miRNA-based) 
therapeutic approaches to hemoglobinopathies [78]. 





























































































































Fig. 6 Time- and concentration-dependent luciferase activity in response to hydroxyurea treatment of anti-miR-26b transfected K562 cells. Inhibi-
tion of miR-26b results in a significant (p < 0.02) increase in luciferase activity and a sigmoidal pattern of action during a time course with HU treat-
ment, with the highest luciferase activity observed after 12 h of treatment (a). A concentration gradient of anti-miR-26b demonstrates an inverse 
relationship between anti-miR26b concentration and MYB-3′-UTR luciferase activity. This unequivocally demonstrates interaction between miR-26b 
and the 3′-UTR of MYB (b). The likely implication of this result is that the miR-26b-induced translational inhibition of MYB (a known activator of KLF-1) 
could result in down-regulation of KLF-1, which is known to directly induce BCL11A expression. In sum, miR-26b could explain the observed up-








Fig. 7 Hydroxyurea mechanisms of HbF induction: regulators and 
miRNAs mediated actions. Proposed HU-induced miRNAs-mediated 
mode of indirect HbF regulation through critical regulators (MYB/KLF-
1/BCL11A) and possibly directly modulating HbF
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other diseases have demonstrated a promising future 
for miRNA-based therapeutics such as the liposome-
based human miR-34 mimic (MRX-34) miRNA-based 
drug against hepatocellular carcinoma (NCT01829971). 
MiRNAs have also been implicated in many cancers 
(colorectal, cervical, prostate, breast and lung) as either 
biomarkers and/or highlighted for potential therapeutic 
significance [79]. Closer to hemoglobinopathies, several 
miRNAs have been associated with specific phenotypes 
or key signalling pathways in SCD; miR-15a and miR-
16-1 with hereditary persistence of HbF [53], miR-148a 
with DNMT-1 [72], miR-144 and tolerance of oxidative 
stress and anemia severity [52], a mouse model show-
ing the correction of SCD via interference with the “fetal 
switch” [80, 81], in vivo association of miR-26b and miR-
151-3p with HU treatment at MTD [44], miR-320 and 
down-regulation of CD71 during terminal differentiation 
of reticulocytes [51], miR-24 and inhibition of erythro-
poiesis via activin type I receptor ALK4 [82], a suite of 
miRNAs including miR-451 in Plasmodium falciparum 
parasite interactions with erythrocytes [83] and now in 
this study, miR-26b direct interaction with MYB 3′-UTR 
and the rescue of miR-26b inhibition with HU treatment.
It is however noteworthy to consider the myriad of 
challenges in miRNAs-based therapies including site-
specificity, delivery and treatment efficacies, off-targeting 
and side effects [84], undesired in vivo pharmacokinetics 
[85] and short half-life in peripheral blood before renal 
clearance [86]. These challenges may also be com-
pounded by the rapid erythrocyte turnover and anemia 
in SCD, the heterogeneous multi-organ complications 
and the numerous genetic polymorphisms affecting dis-
ease severity, predisposition to specific phenotypes, 
the vast variation in response to HU treatment and the 
overall clinical course of the disease [60]. Although faced 
with many challenges, novel methodologies such as exo-
some-based delivery systems provide sufficient evidence 
in support of the continued efforts to develop improved 
systems of delivery and target-specificity, desired in vivo 
stability, reduced side- and off-target effects for miRNA-
based therapeutic approaches [87–89].
Conclusion
In the present article, the authors have demonstrated 
successful expansion and differentiation of umbilical 
cord blood-derived CD34+ HSCs into CD71+/CD235a+ 
erythroid cells and showed HU-mediated induction of 
γ-globin expression concomitant with the down-reg-
ulation of key negative regulators, BCL11A, MYB and 
KLF-1. Importantly, the experiments have demonstrated 
association between the induction of miR-15a and miR-
16-1 and HU-mediated down-regulation of MYB as well 
as up-regulation of miR-148a, which targets DNMT-1. 
Furthermore, the data have shown the direct interaction 
between miR-26b and the MYB 3′-UTR, possible indirect 
modulation of BCL11A via MYB activation of KLF-1, all 
of which were concomitant with HbF production in both 
erythroid and K562 cells. The results of this study dem-
onstrate the role of miRNAs in the modulation of HbF, 
directly and through critical regulators. The elucidation 
of the post-transcriptional regulation of HbF through 
miRNAs could incite investigation of therapeutic agents 
that would avoid global transcriptome changes but 
rather hone in on critical regulators with lineage-specific 




Umbilical cord blood was harvested during elective cae-
sareans at Mowbray Maternity Hospital (Cape Town, 
South Africa) from healthy females of black African ori-
gins, free of the sickle cell mutation. Cord blood (90–
140 ml) was collected in anticoagulant citrate phosphate 
dextrose adenine (CPDA-1)-containing bags (SSEM 
Mthembu, South Africa) and processed within 4  h of 
harvest.
Isolation of CD34+ hematopoietic cells
Cord blood samples were diluted using Iscove’s Modified 
Dulbecco Medium (Sigma, SA), layered on Ficoll-His-
topaque (1.077 g/ml) (Sigma, SA), centrifuged to collect 
the mononuclear cell layer (MNCL), then enriched for 
CD34+ hematopoietic stem cells (HSCs) using Dynabead 
magnetic separation technology according to manufac-
turer’s instructions (Life Technologies, SA).
Flow cytometry
The purity of the Dynabead-selected HSCs and differen-
tiated erythroid cells was determined using cell-surface 
antibodies and flow cytometry (FACSCalibur, BD Bio-
sciences, USA). Briefly, 5 × 104 HSCs were stained with 
phycoerythrin-conjugated CD34 (CD34-PE) and fluo-
rescein isothiocyanate-conjugated CD45 (CD45-FITC) 
(BD Biosciences, USA) according to the manufacturer’s 
instructions and analysed. Subsequent to erythroid dif-
ferentiation, markers of the derived-erythroid cells were 
analysed on day 15 using CD34-PE, CD45-APC, CD71-
FITC and CD235a-PE (BD Biosciences, USA). The con-
trols included in the flow cytometry experiments were 
as follows: (i) No cells (cell suspension fluid: 1x PBS), 
(ii) Cells only, (iii) Cells and primary antibody only, (iv) 
Cells and secondary antibody only. These were included 
to ensure specificity in antigen–antibody interactions 
in the experiments. During optimization, a separate 
cell line, RAMOS (RA-1 CRL1596, ATCC) was used to 
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independently confirm the specificity of the primary anti-
bodies (CD34, CD45, CD71 and CD235a) compared to 
K562 cells (using ATCC reference expression levels and 
those determined in our lab) and HSC-derived erythroid 
cells.
Hematopoietic colony assay
Colony-forming unit-granulocyte, erythroid, mono-
cyte, megakaryocyte (CFU-GEMM) hematopoietic col-
ony assays were performed using 1 ×  104 HSCs seeded 
in semi-solid agar plates supplemented with 30  % fetal 
bovine serum (FBS) (Biochrom, Germany), 1 U/ml EPO, 
200  ng/ml SCF, 10  ng/ml of both granulocyte-colony 
stimulating factor (G-CSF) and interleukin-3 (IL-3). The 
colonies were counted after 14 days in culture. After glut-
araldehyde fixing, cultures were lifted, mounted on slides 
and stained with May-Grundwald and Giemsa stains 
then visualized under the microscope.
Cell culture
CD34+ cells were cultured using a single-phase ex  vivo 
expansion and differentiation protocol [53] with minor 
modifications. Briefly, cells were cultured in IMDM sup-
plemented with 2  U/ml erythropoietin (EPO) (Sigma-
Aldrich, Chemie GmbH Germany), 1 μM glucocorticoid 
dexamethasone (Sigma-Aldrich, Chemie GmbH Ger-
many), 40  ng/ml insulin-like growth factor 1 (IGF-1) 
(Sigma-Aldrich, South Africa), 100  ng/ml stem cell fac-
tor (SCF) (Sigma-Aldrich, Chemie GmbH Germany) and 
400 μg/ml holo-human transferrin (Sigma-Aldrich, Ger-
many). The initial seeding density of 0.5−1 ×  106 cells/
ml were expanded and differentiated to erythroid pro-
genitors for 15 days, with ad hoc demi-population. Post-
differentiation, flow cytometry was used to determine 
expression of CD71 and CD235a (Glycophorin-A). The 
human erythroleukaemia cell line K562 was cultured in 
IMDM initially supplemented with 10  % FBS and then 
0.5 % in all subsequent experiments.
Cell proliferation assay
The determine the optimal concentration and exposure 
time to HU, K562 cells treated and analysed using the 
WST-1 Cell Proliferation Assay (Roche) 2, 4, 6, 12 and 
24 h after treatment. Briefly, the assay is a non-radioac-
tive, spectrophotometric method to quantify cell prolif-
eration and viability in response to HU treatment. A final 
concentration of 100  µM of HU was used in all subse-
quent experiments.
Gene expression
Total RNA was isolated from both human erythroid and 
K562 cells using the Qiagen AllPrep DNA/RNA/miRNA 
Kit (Qiagen, USA) in accordance with the manufacturer’s 
instructions. Total RNA was used for mRNA and miRNA 
cDNA syntheses using the High-Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, UK) and the miS-
cript II Reverse Transcription Kit (Qiagen, USA), respec-
tively. To investigate their suitability as internal control 
genes, the expressions of RPS17, RSP20 and GAPDH were 
analysed in cells treated with HU. The expression of all three 
genes were relatively unaffected by the drug, and RPS20 was 
chosen as the reference gene in all subsequent qPCR assays 
as it was least affected by the treatment. In order to explore 
a potential mechanism of post-transcriptional regulation, 
changes in expression of seven targeted miRNAs, previously 
shown to target MYB (miR-15a and miR-16-1) [53]; modi-
fied by HU (miR-148a, miR-151-3p and miR-494); associ-
ated with basal γ-globin expression (miR-26b) and with HbF 
at MTD (miR-451) [44] were also examined using miScript 
primer assays. Gene expression analysis was conducted 
using SYBR Green-based qPCR and individual primer 
assays for differential miRNA expression analysis and per-
formed on the CFX96 Real-Time instrument (BioRad, 
USA). The controls used when the differential expression of 
miRNAs was investigated using commercially available sin-
gle primer assays (Qiagen, USA) were samples with (i) No 
RNA, (ii) No reverse transcriptase and (iii) C. elegans spike-
controls in cDNA synthesis and (iv) No cDNA control in the 
PC reaction. To use for normalization, the expressions of 
miRNAs SNORD68, SNORD95 and RNU6-2 were analysed 
for differential regulation by HU. Their expressions were 
relatively unaffected, and miRNA RNU6-2 was chosen as 
the reference gene for all subsequent assays due to its higher 
stability.
Transfection
To establish whether there is a direct relationship 
between miRNAs and γ-globin expression upon treat-
ment with HU, K562 cells were transfected with anti-
miRNAs, individually as well as in various combinations. 
Cells were transfected with human miScript miRNAs 
inhibitors (anti-miRNAs) (Qiagen, USA); anti-miR-
26b-5p, anti-miR-151a-3p, anti-miR-451a and anti-miR-
494-3p using XtremeGene HP (Roche) for 24  h and 
treated with HU. To ensure that the transfection reagent 
(TR) did not affect HbF expression, no TR controls were 
included during miRNA and western blot assay optimiza-
tion. In addition, the expression of genes was measured 
relative to cells transfected with the miScript inhibitor 
Negative Control (Qiagen, USA), which is a commercially 
available scrambled anti-miRNA that has no consensus 
with any known human miRNAs.
Western blot
Cells were suspended in RIPA lysis buffer (150 Mm NaCl, 
1 % Triton X100, 0.1 % SDS, 10 Mm Tris pH 7.5 and 1 % 
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deoxycholate powder) and lysed overnight at −80 °C. The 
BCA kit (Pierce BCA Protein Assay kit, Thermo Scien-
tific, USA) was used to quantify protein from total cell 
lysates and 15 μg of protein for each sample was loaded 
and separated on 15  % SDS-PAGE gels and transferred 
onto nitrocellulose membranes. Anti-fetal hemoglobin 
primary antibody was used at 1:1000 dilution (ab156584, 
Abcam, RSA), for loading control, 1:5000 dilution of anti-
p38 (BioRad, USA) and 1:5000 dilution of goat anti-rabbit 
IgM horse radish peroxidase (HRP) conjugate secondary 
antibody (BioRad, USA) were used. Blots were developed 
using the Clarity ECL substrate (BioRad, USA).
Luciferase assays
Dual-luciferase reporter assays (Promega, USA) were 
conducted using the pGL3-MYB-3′-UTR to investigate 
potential direct interactions between our candidate miR-
NAs and the MYB 3′-UTR (1191 base pairs) using the 
pGL3-MYB-3′UTR (Addgene, USA). The pGL3-MYB-
3′-UTR vector contained a 1191 bp insert of the c-MYB 
3′-UTR. The pGL3-basic vector was used as a control in 
the luciferase assays. The bacterial stab (growth strain 
DH5α) was streaked on Luria broth (LB) (Sigma-Aldrich, 
SA) plates and grown overnight at 37 °C with ampicillin 
antibiotic (100  µg/ml) and single colonies were inocu-
lated in liquid cultures. The plasmids were recovered 
using the PureYield Plasmid Miniprep and Maxiprep kits 
(Promega, USA) and quantified using a nanodrop spec-
trophotometer (NanoDrop, USA). To confirm presence 
of the c-MYB 3′-UTR insert, restriction enzyme digests 
and agarose gel electrophoresis were performed. As fur-
ther confirmation, the vectors were sequenced using 
RV-primer four (Molecular Cell Biology Department, 
University of Cape Town).
K562 cells were co-transfected with the luciferase 
reporter vectors and anti-miRNAs using XtremeGene 
HP DNA transfection reagent (Roche, USA) according 
to manufacturer’s instructions. All transfections included 
a pRL reporter vector with Renilla luciferase cDNA, to 
which all MYB-3′-UTR luciferase activity was normalized 
(MYB-3′-UTR: pRL-TK). Cells were lysed and the super-
natant collected for analysis using the Luciferase assay 
reagent II (LARII) (Promega, USA) in a 96-well luciferase 
assay plate. The Glomax Multi-Detection system (Pro-
mega, USA) was used to measure the luminescence and 
the Stop & Glo reagent (Promega, USA) to quantify the 
Renilla luciferase signal for each well. The pGL3-basic 
vector was used as a baseline reference for all experimen-
tal wells with the results given as fold change of normal-
ized luciferase signal over baseline.
The pGL3-Basic or Empty vector was used as a control 
to check if any of the co-transfected anti-miRNAs had 
background interaction with the backbone of the vector. 
There was no such interaction even when cells with the 
basic/empty vector were treated with HU. Luciferase 
activity was also measured in cells transfected with the 
pGL3-MYB-3′-UTR vector but not treated with HU in 
order to assess the effect of basal miRNAs on the 3′-UTR.
Statistical analysis
For each gene expression experiment in K562 cells, three 
technical repeats (same experiment) and three inde-
pendents experimental repeats were performed. Rela-
tive quantification using ΔCq values was calculated in 
accordance with the Pfaffl et  al. method [90]. Statistical 
analysis was done using the student t test on ΔCq values 
and a p value of 0.05 or less was considered significant.
Additional files
Additional file 1: Figure S1. Time dependent expression of markers of 
late erythroid differentiation (CD235a and CD71) in erythroid cells treated 
with HU. Expression of CD235a (A) and CD71 (B) during late erythroid dif-
ferentiation show no significant differences between HU treated (+) and 
untreated (−) cells. The lack of significant changes in the expression of 
these markers is indicates that HU had minimal effect on the processes of 
erythroid differentiation, thus suggesting that the results, particularly the 
induction of γ-globin and repression of BCL11A, KLF-1 and MYB, were not 
artefacts of stress erythropoiesis.
Additional file 2: Figure S2. Time-dependant effect of hydroxyurea on 
cellular metabolic activity. To determine the optimal exposure time to HU 
(100 μM previously determined to be the optimal concentration), K562 
cells (8 × 104 cells/100 μl) were plated in a 96-well dish in triplicates and 
treated with 100 μM hydroxyurea for 2, 4, 6, 12 and 24 h. Six (6) and 12 h 
exposure times were determined to be optimal as at this time point, the 
initial cytotoxic surge of HU had subsided and sufficient cells remained 
metabolically active to alter gene expression in response to the treatment. 
This determination was also supported by the fact that HU is prescribed to 
SCD patients as an oral pill taken daily, thus suggesting that the treatment 
takes most effect between 6 and 12 h after treatment.
Additional file 3: Figure S3.  Time-dependent effect of hydroxyurea on 
miRNAs expression in K562 cells. HU caused sigmoidal time-dependent 
changes in miRNAs expression in K562 cells with significant up-regulation 
of all miRNAs except miR-26b and miR494 (although not statistically 
significant, but also peaking in expression 6 h post treatment). MiR-16-1 
and miR151-3p had a 4.5-fold up-regulation, which was associated with 
the most apparent induction of HbF at 6 h after HU treatment.
Additional file 4: Figure S4. Time dependent luciferase activity in 
response to HU treatment of anti-miR-151-3p; anti-miR-451 and anti-
miR-494 transfected K562 cells. Luciferase activity was highest after 6 and/
or 12 h of HU treatment in for all anti-miRNAs, demonstrating a sigmoidal 
pattern of luminescence. Although less apparent as compared to anti-
miR-26b, the anti-miR-151-3p concentration gradient also showed a 
similar gradual increase in luciferase activity associated with the decrease 
in anti-miR-151-3p concentration (A and B). There was minimal data to 
suggest interaction between the MYB-3′-UTR and miR-451 and miR-494, 
in a 24-hour time course experiment (C and D).
Additional file 5: Figure S5. Concentration-dependent inhibition of 
miR-26b; miR-151-3p; miR-451 and miR-494 down-regulates HbF protein 
in K562 cells. HbF protein was reduced at higher concentration of all 
anti-miRNAs. This suggests that most miRNAs target negative regulators 
of HbF as their inhibition causes up-regulation of γ-globin expression. It is 
possible that like miR-26b, a suite of other HU-responsive miRNAs could 
modulate HbF production through regulation of positive and negative 
regulators of γ-globin.
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